Karyopharm Therapeutics Inc. received a deficiency letter from Nasdaq stating that its common stock has closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Select Market.
AI Assistant
KARYOPHARM THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.